What SEC filings does Organogenesis Holdings Inc. submit to the SEC?

Organogenesis Holdings Inc. (ORGO) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ORGO?

A Form 4 for ORGO discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Organogenesis Holdings Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ORGO?

The 10-K is Organogenesis Holdings Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ORGO SEC filings directly on EDGAR?

You can view all historical Organogenesis Holdings Inc. filings on the SEC EDGAR company page for ORGO. Each filing card on this page links directly to the original SEC document.

How often does Organogenesis Holdings Inc. file with the SEC?

Organogenesis Holdings Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ORGO shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

ORGO SEC Filing News — Organogenesis Holdings Inc.

Latest SEC filings for Organogenesis Holdings Inc. (ORGO) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-06.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatm…

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $131.2M CIK: 1661181

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for ORGO currently lean bullish. Of the 20 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 11 insider transactions (Form 4) in this period.

ORGO Filing Activity Snapshot 2026-02-20 — 2026-08-06

Insider Transactions (Form 4)

2 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$26.7K

Driscoll Michael Joseph (Director) · 2026-03-11

10,000 shares · Form 4

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Organogenesis Holdings Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 7 compensation award, 2 open-market purchase, 1 option exercise and 1 tax withholding. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×2: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Tax withholding ×1: Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Form 4 Option exercise Tax / Compensation Filing 2026-04-24

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Grow Brian (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	958	$1.24	$1.2K
`M`	Option exercise derivative · Stock Option (Right to Buy)	958	—	—

Filing: Form 4 (Insider Transaction) Insider: Grow Brian (Chief Commercial Officer) Shares: 958

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-03-11

ORGO insider Leibowitz Arthur S (Director) bought 5,000 shares (~$13.4K)

Leibowitz Arthur S, listed as Director at Organogenesis Holdings Inc., reported an open-market purchase of 5,000 ORGO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	5,000	$2.68	$13.4K

Filing: Form 4 (Insider Transaction) Insider: Leibowitz Arthur S (Director) Shares: 5,000 Est. Value: $13.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-03-11

ORGO insider Driscoll Michael Joseph (Director) bought 10,000 shares (~$26.7K)

Driscoll Michael Joseph, listed as Director at Organogenesis Holdings Inc., reported an open-market purchase of 10,000 ORGO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	10,000	$2.67	$26.7K

Filing: Form 4 (Insider Transaction) Insider: Driscoll Michael Joseph (Director) Shares: 10,000 Est. Value: $26.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-03-03

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Cavorsi Robert (Vice President, Strategy) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	700	$3.21	$2.2K

Filing: Form 4 (Insider Transaction) Insider: Cavorsi Robert (Vice President, Strategy) Shares: 700

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-02-20

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Freedman Lori (Chief Admin. and Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	203,125	—	—
`A`	Compensation award	42,780	—	—
`F`	Tax withholding on vested shares	14,267	$3.84	$54.8K
`A`	Compensation award derivative · Stock Option (Right to Buy)	115,812	—	—

Filing: Form 4 (Insider Transaction) Insider: Freedman Lori (Chief Admin. and Legal Officer) Shares: 260,172

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-02-20

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	93,750	—	—
`A`	Compensation award	16,290	—	—
`F`	Tax withholding on vested shares	5,432	$3.84	$20.9K
`A`	Compensation award derivative · Stock Option (Right to Buy)	53,452	—	—

Filing: Form 4 (Insider Transaction) Insider: Cavorsi Robert (Vice President, Strategy) Shares: 115,472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-02-20

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Francisco David (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	195,312	—	—
`A`	Compensation award	43,602	—	—
`F`	Tax withholding on vested shares	14,541	$3.84	$55.8K
`A`	Compensation award derivative · Stock Option (Right to Buy)	111,358	—	—

Filing: Form 4 (Insider Transaction) Insider: Francisco David (Chief Financial Officer) Shares: 253,455

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-02-20

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Grow Brian (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	234,375	—	—
`A`	Compensation award	48,330	—	—
`F`	Tax withholding on vested shares	11,768	$3.84	$45.2K
`A`	Compensation award derivative · Stock Option (Right to Buy)	133,630	—	—

Filing: Form 4 (Insider Transaction) Insider: Grow Brian (Chief Commercial Officer) Shares: 294,473

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-02-20

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Bilbo Patrick (Chief Operating Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	210,937	—	—
`A`	Compensation award	48,612	—	—
`F`	Tax withholding on vested shares	16,212	$3.84	$62.3K
`A`	Compensation award derivative · Stock Option (Right to Buy)	120,267	—	—

Filing: Form 4 (Insider Transaction) Insider: Bilbo Patrick (Chief Operating Officer) Shares: 275,761

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-02-20

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Gillheeney Gary S. (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	890,625	—	—
`A`	Compensation award	186,968	—	—
`F`	Tax withholding on vested shares	90,398	$3.84	$347.1K
`A`	Compensation award derivative · Stock Option (Right to Buy)	507,795	—	—

Filing: Form 4 (Insider Transaction) Insider: Gillheeney Gary S. (Director, President and CEO) Shares: 1,167,991

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-02-20

ORGO insider Form 4 filed for equity award, exercise, or tax withholding

Driscoll Michael Joseph (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	48,828	—	—

Filing: Form 4 (Insider Transaction) Insider: Driscoll Michael Joseph (Director) Shares: 48,828

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for Organogenesis Holdings Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-06

ORGO filed 8-K — material company event

Organogenesis Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-06

ORGO filed 8-K — material company event

Organogenesis Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-16

ORGO filed 8-K — material company event

Organogenesis Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-07

ORGO filed 8-K — material company event

Organogenesis Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-02-26

ORGO filed 8-K — material company event

Organogenesis Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-02-23

ORGO filed 8-K — material company event

Organogenesis Holdings Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for Organogenesis Holdings Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

ORGO filed Quarterly Report (10-Q)

Organogenesis Holdings Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-07

ORGO filed Quarterly Report (10-Q)

Organogenesis Holdings Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-K Annual Report 2026-02-26

ORGO filed Annual Report (10-K)

Organogenesis Holdings Inc. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

View on SEC EDGAR → Open Filing Document →

How we classify Organogenesis Holdings Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on ORGO. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — ORGO SEC Filings

More Tools for ORGO

ORGO Full Stock Analysis ORGO Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper ORGO analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the ORGO stock analysis page.

ORGO Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer